Biolargo Stock Price, News & Analysis

BioLargo (OTCQX:BLGO), an environmental and cleantech solutions company, announced the approval of all matters at its 2025 annual stockholder meeting. While shareholders approved a potential 10-for-1 reverse stock split, management clarified they have no immediate plans to implement it.

CEO Dennis Calvert emphasized that the company would only consider the reverse split if needed to meet minimum price requirements for uplisting to Nasdaq or NYSE. BioLargo currently meets all uplisting qualifications except for stock price, and management views this approval as strategic preparation for potential future opportunities.

BioLargo (OTCQX:BLGO) has received independent validation from U.S. BESS Corporation confirming breakthrough performance of its Cellinity battery technology for grid-scale energy storage. The evaluation verified impressive specifications including >4.2V open circuit voltage, 120-250°C operating range, >500 Wh/kg energy density, and ~100% charge/discharge efficiency. Key advantages include no thermal runaway risks, domestically sourceable materials, absence of rare earth elements, and full recyclability. The technology addresses critical limitations of current lithium-ion batteries amid rapidly growing demand for grid storage, with U.S. battery storage capacity increasing 66% in 2024. BioLargo is now working on scaling up cell design and manufacturing, while pursuing manufacturing joint ventures for commercialization.

BioLargo (OTCQX:BLGO), a company focused on sustainable environmental and health technologies, has scheduled its Q1 2025 earnings conference call and webcast for Thursday, May 15, 2025, at 4:30 PM Eastern Time. The event will cover financial results for the quarter ending March 31, 2025, recent company milestones, and include a Q&A session.

Participants can join via webcast or teleconference, with domestic and international dial-in numbers provided. The webcast replay will be available until August 15, 2025, while the teleconference replay will be accessible until May 29, 2025. All presentation materials will be posted on BioLargo's investor relations website.

BioLargo (OTCQX:BLGO) announced that its subsidiary Clyra Medical Technologies has secured multiple distribution agreements for its medical products in domestic and international markets. While these agreements don't include minimum purchase requirements, they each have the potential to generate significant revenue for Clyra. CEO Dennis P. Calvert highlighted the company's investment in meeting client specifications and bringing products to market, though no specific timeline or sales volume predictions were provided.

BioLargo (OTCQX:BLGO) has revealed case study data demonstrating that its AEC (Aqueous Electrostatic Concentrator) PFAS solution can achieve over 80% lifecycle cost savings compared to traditional carbon-based treatment systems. The technology effectively captures and destroys PFAS contamination to non-detect levels in drinking water, wastewater, and landfill leachate.

The significant cost reduction is attributed to the AEC's ability to generate less PFAS-laden waste compared to conventional methods like granular activated carbon (GAC) and ion exchange resins, coupled with lower replacement costs for treatment materials. Unlike traditional methods, the AEC doesn't suffer from breakthrough or channeling phenomena, particularly with short chain PFAS, leading to reduced maintenance frequency and better PFAS capture efficiency.

BioLargo (OTCQX: BLGO), a cleantech and environmental solutions company, has announced its participation in the upcoming 15th Annual LD Micro Invitational at the Westin Grand Central in New York. The company's President & CEO Dennis P. Calvert will deliver a presentation on April 10, 2025, at 2:30 PM Eastern Time, covering the company's financial performance from the previous year and current business initiatives.

The LD Micro Invitational XV is scheduled for April 9-10, 2025, featuring over 50 presenting companies. The event will commence with registration at 2:00 PM ET on April 9th, followed by keynote speeches. Companies will present in 30-minute segments and participate in private investor meetings throughout the two-day conference.

BioLargo (OTCQX:BLGO) reported record-breaking financial results for 2024, marking its tenth consecutive year of revenue growth. The cleantech company achieved revenues of $17.77 million, representing a 45% increase from 2023. The company's net loss decreased by 6% to $4.34 million, with $3.49 million attributed to Clyra Medical operations.

The company's financial position showed improvement with $3.54 million in cash, total assets of $10.51 million, and stockholders' equity of $6.05 million. BioLargo reduced its reliance on equity financing, issuing 42% fewer shares compared to 2023. The company generated over $5 million from odor control products and continues to develop emerging technologies, including Clyra surgical products, PFAS water treatment solutions, and Cellinity battery storage technology.

BioLargo (OTCQX:BLGO), a developer of sustainable technologies and full-service environmental engineering company, has scheduled its Year-End 2024 earnings results webcast and conference call for Monday, March 31, 2025, at 4:00 PM Eastern Time (1:00 PM Pacific).

The public event will cover the company's financial results for the year ended December 31, 2024, discuss recent milestones, and include a question-and-answer session. Participants can join via webcast or teleconference, with replay access available until July 1, 2025 for the webcast and April 14, 2025 for the teleconference.

BioLargo (OTCQX:BLGO) has been invited to present at the Air & Waste Management Association's 'The Science of PFAS' conference on March 12, 2025. The company will showcase its Aqueous Electrostatic Concentrator (AEC) technology's successful results in removing and destroying PFAS from landfill leachate.

The AEC technology demonstrates unique capabilities in PFAS treatment, achieving 'non-detect' levels (less than 1 part per trillion) for all PFAS types (short, medium, and long-chain), while producing only inert salts as byproducts. The system selectively captures PFAS from water, wastewater, and landfill leachate without generating significant waste.

Tonya Chandler, President of BioLargo Equipment Solutions & Technologies, will present these findings at the conference, which brings together environmental professionals, regulators, and researchers from across 65 countries.